NeuroSense Therapeutics (NRSN) Competitors $2.03 -0.02 (-0.98%) Closing price 04:00 PM EasternExtended Trading$2.02 -0.01 (-0.74%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRSN vs. HLVX, TCRX, SAVA, ANIX, COYA, CRBP, HURA, MGNX, ZNTL, and OPTNShould you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include HilleVax (HLVX), TScan Therapeutics (TCRX), Cassava Sciences (SAVA), Anixa Biosciences (ANIX), Coya Therapeutics (COYA), Corbus Pharmaceuticals (CRBP), TuHURA Biosciences (HURA), MacroGenics (MGNX), Zentalis Pharmaceuticals (ZNTL), and OptiNose (OPTN). These companies are all part of the "pharmaceutical products" industry. NeuroSense Therapeutics vs. Its Competitors HilleVax TScan Therapeutics Cassava Sciences Anixa Biosciences Coya Therapeutics Corbus Pharmaceuticals TuHURA Biosciences MacroGenics Zentalis Pharmaceuticals OptiNose NeuroSense Therapeutics (NASDAQ:NRSN) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk. Does the media prefer NRSN or HLVX? In the previous week, NeuroSense Therapeutics had 1 more articles in the media than HilleVax. MarketBeat recorded 2 mentions for NeuroSense Therapeutics and 1 mentions for HilleVax. NeuroSense Therapeutics' average media sentiment score of 0.00 equaled HilleVax'saverage media sentiment score. Company Overall Sentiment NeuroSense Therapeutics Neutral HilleVax Neutral Which has more volatility & risk, NRSN or HLVX? NeuroSense Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, HilleVax has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Is NRSN or HLVX more profitable? NeuroSense Therapeutics' return on equity of 0.00% beat HilleVax's return on equity.Company Net Margins Return on Equity Return on Assets NeuroSense TherapeuticsN/A N/A -445.40% HilleVax N/A -51.86%-41.45% Do analysts prefer NRSN or HLVX? NeuroSense Therapeutics currently has a consensus target price of $14.00, suggesting a potential upside of 589.66%. HilleVax has a consensus target price of $2.00, suggesting a potential downside of 6.54%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe NeuroSense Therapeutics is more favorable than HilleVax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroSense Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00HilleVax 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has stronger earnings and valuation, NRSN or HLVX? NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroSense TherapeuticsN/AN/A-$10.21M-$0.54-3.76HilleVaxN/AN/A-$147.27M-$2.15-1.00 Do insiders & institutionals hold more shares of NRSN or HLVX? 1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of HilleVax shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Comparatively, 24.9% of HilleVax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryNeuroSense Therapeutics beats HilleVax on 10 of the 13 factors compared between the two stocks. Get NeuroSense Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRSN vs. The Competition Export to ExcelMetricNeuroSense TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.75M$3.06B$5.67B$9.49BDividend YieldN/A2.44%4.05%4.00%P/E Ratio-3.7620.8627.9419.95Price / SalesN/A246.06396.5882.68Price / CashN/A41.9636.1958.45Price / Book10.688.308.635.82Net Income-$10.21M-$55.19M$3.24B$258.42M7 Day Performance3.05%5.07%3.22%1.94%1 Month Performance-12.12%17.61%10.72%12.02%1 Year Performance144.87%7.03%34.94%20.80% NeuroSense Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRSNNeuroSense Therapeutics2.125 of 5 stars$2.03-1.0%$14.00+589.7%+162.5%$27.75MN/A-3.7610HLVXHilleVax1.3659 of 5 stars$2.17+3.8%$2.00-7.8%+8.2%$108.81MN/A-1.0120Positive NewsTCRXTScan Therapeutics3.2301 of 5 stars$1.92+6.1%$7.80+306.3%-74.3%$108.66M$4.42M-1.76100SAVACassava Sciences4.1269 of 5 stars$2.16+1.4%$54.50+2,423.1%-77.6%$104.35MN/A-1.4430News CoveragePositive NewsANIXAnixa Biosciences3.1654 of 5 stars$3.20+1.9%$9.00+181.3%+17.0%$103.07M$210K-8.425COYACoya Therapeutics1.9656 of 5 stars$6.16+0.5%$16.50+167.9%-15.5%$103.03M$3.69M-5.766News CoverageAnalyst ForecastCRBPCorbus Pharmaceuticals4.7625 of 5 stars$8.36+1.1%$50.88+508.6%-84.8%$102.33MN/A-1.9840HURATuHURA Biosciences1.8206 of 5 stars$2.33+1.3%$12.67+443.6%N/A$101.77MN/A0.00N/AMGNXMacroGenics4.1954 of 5 stars$1.58-1.9%$5.71+261.7%-66.0%$99.68M$152.43M-1.78430News CoverageZNTLZentalis Pharmaceuticals1.708 of 5 stars$1.36+2.3%$8.37+515.2%-64.1%$97.85M$67.43M-0.43160News CoveragePositive NewsOPTNOptiNose0.752 of 5 stars$9.60flat$9.00-6.3%N/A$97.22M$81.86M-2.29190 Related Companies and Tools Related Companies HLVX Competitors TCRX Competitors SAVA Competitors ANIX Competitors COYA Competitors CRBP Competitors HURA Competitors MGNX Competitors ZNTL Competitors OPTN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRSN) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
